Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Broking boss makes £2.6m profit

Mon, 02nd Nov 2009 16:30

Evolution chief executive Alex Snow has sold £5.2m of shares after being awarded 4.59m shares from two company option schemes after the vesting conditions for the shares were met. The Evolution Group Plc 2000 Executive Share Option Scheme issued 3.09m shares to Snow, Of these, 2.026m did not have any performance criteria, while the award of the rest was based on share price performance. These shares were acquired at 58.67p a share. The total cost was £1.81m. The other 1.5m shares were issued under the Evolution Group Plc 2001 Executive Share Option Scheme - following the achievement of share price performance criteria - and they cost 52.3p each. The total cost was £785,000. That means that Snow made a £2.6m profit on the share sales, which were at 163p a share. The share price is the highest it has been for more than three years. He retains 1.4m of the shares that he was awarded. This still leaves Snow with a higher percentage of the company. He owns 5.6m shares, which is equivalent to 2.42% of Evolution. Snow has taken up all the shares he had under option at the time of the 2008 annual report. Last week, the broker announced that its 2009 profits would be better than expected. Corporate activity has increased in the second half of the year. Funds under management have grown to £5bn at the end of September 2009. In April, Snow raised nearly £927,000 by selling shares at 114p each. That followed the exercise of options over 2m shares at 1p each - a total cost of £20,000. Snow said that the sale proceeds paid for the options and associated tax costs. That means that Snow has made more than £3.5m profit from share sales this year, while retaining 2.57m shares he has been awarded. Top Director BuysAccess Intelligence (ACC) Director name: Mr David LoweAmount purchased: 961,111 @ 4.70p Value: £45,172CLS Holdings (CLI) Director name: Mr Sten A MortstedtAmount purchased: 7,940 @ 443.00p Value: £35,174Jetion Solar Holdings (JHL) Director name: Mr Raymond WongAmount purchased: 30,000 @ 64.50p Value: £19,350Top Director SellsEvolution Group (EVG) Director name: Mr Alex SnowAmount sold: 3,191,565 @ 163.00p Value: £5,202,251Diageo (DGE) Director name: Mr Paul S WalshAmount sold: 99,000 @ 1,000.00p Value: £990,000
More News
8 Jun 2020 16:06

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
13 Feb 2020 16:17

Evgen Pharma, Rochester University To Advance SFX-01 For Trial

Evgen Pharma, Rochester University To Advance SFX-01 For Trial

Read more
6 Feb 2020 13:45

Evgen Pharma Hails "Positive" Data From Breast Cancer Drug Research

Evgen Pharma Hails "Positive" Data From Breast Cancer Drug Research

Read more
17 Dec 2019 15:35

Evgen Pharma narrows loss, foresees 'clinical success'

(Sharecast News) - Evgen Pharma on Tuesday reported a narrowed interim loss and said it was confident of clinical success as it continues to develop its SFX-01 treatment.

Read more
17 Dec 2019 11:28

Evgen Pharma Outlook Confident Amid Clinical Success And Trimmed Loss

Evgen Pharma Outlook Confident Amid Clinical Success And Trimmed Loss

Read more
10 Dec 2019 15:59

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
5 Dec 2019 16:36

Evgen Pharma to advance SFX-01 trial with University of Dundee

(Sharecast News) - Clinical-stage drug development company Evgen Pharma has entered into a memorandum of understanding with the University of Dundee, it announced on Thursday, to advance SFX-01 towards a clinical trial in non-alcoholic steatohepatitis (NASH) and liver fibrosis.

Read more
5 Dec 2019 15:19

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

Evgen Pharma, University Of Dundee To Collaborate To Advance SFX-01 Trials

Read more
11 Nov 2019 12:23

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

UPDATE: Evgen Pharma "Unlikely" To Pursue Subarachnoid Development

Read more
11 Nov 2019 10:22

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

UK WINNERS & LOSERS SUMMARY: Greggs Surges 17% After Raising Guidance

Read more
11 Nov 2019 09:11

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Evgen Pharma Shares Drop On "Disappointing" SFX-01 Trial Results

Read more
23 Sep 2019 13:09

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results

Read more
23 Sep 2019 10:03

Evgen Pharma upbeat on latest news from SFX-01 studies

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Monday that five patients who participated in the 'STEM' trial received 'SFX-01' treatment for more than one year, with two of those patients continuing to be treated with SFX-01.

Read more
28 Aug 2019 14:30

Evgen Pharma completes patient study visits in 'SAS' phase 2 trial

(Sharecast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that the last study visit for the last patient entered in the double-blind, placebo-controlled 'SAS' phase 2 clinical trial has taken place.

Read more
28 Aug 2019 12:06

Evgen Pharma Receives Last Patient For Stroke Treatment Drug Trial

(Alliance News) - Evgen Pharma PLC said Wednesday it has entered its last patient in the double-blind, placebo-controlled SAS Phase II clinical trial that is testing its SFX-01 product, aimed at a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.